Tango Therapeutics to Present Updated Vopimetostat Combination Trial Data at ESMO 2026
Tango Therapeutics will present updated Phase 1/2 vopimetostat combination data at the ESMO Congress in Madrid on Oct. 25, 2026. The study evaluates vopimetostat with daraxonrasib or zoldonrasib in patients with MTAP-deleted, RAS-mutant metastatic pancreatic cancer or non-small cell lung cancer. A pancreatic cancer-foc